Vulva

Protocol applies to invasive carcinomas of the vulva.

Protocol revision date: January 2005
Based on AJCC/UICC TNM, 6th edition and FIGO 2001 Annual Report

Procedures
• Cytology (No Accompanying Checklist)
• Incisional Biopsy (No Accompanying Checklist)
• Excisional Biopsy
• Vulvectomy (With or Without Removal of Other Organs and Tissues)

Author
Philip A. Branton, MD
Department of Pathology, Inova Fairfax Hospital, Fairfax, Virginia
For the Members of the Cancer Committee, College of American Pathologists

Previous contributors: Edward J. Wilkinson, MD; Robert E. Scully, MD
© 2005. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.
Summary of Changes to Checklist(s)

Protocol revision date: January 2005

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.
Surgical Pathology Cancer Case Summary (Checklist)

Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition
and FIGO 2001 Annual Report

VULVA: Excisional Biopsy, Resection

Patient name:
Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC

Specimen Type
___ Local excision
___ Wide excision
___ Partial vulvectomy
___ Total vulvectomy
___ Radical vulvectomy
___ Other (specify): ____________________________
___ Not specified

Lymphadenectomy
___ Not applicable
___ Sentinel lymph node biopsy
___ Inguinal-femoral nodes
___ Pelvic nodes
___ Other (specify): ____________________________

Tumor Site (check all that apply)
___ Right vulva
   * ___ Labia major
   * ___ Labia minor
___ Left vulva
   * ___ Labia major
   * ___ Labia minor
___ Clitoris
___ Other (specify): ____________________________
___ Not specified

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
Tumor Size
Greatest dimension: ___ cm
*Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)

MICROSCOPIC

Histologic Type (check all that apply)
___ Squamous cell carcinoma
    *___ Keratinizing
    *___ Non keratinizing
    *___ Basaloid
    *___ Warty (condylomatous)
    *___ Other (specify): ____________________________
___ Verrucous carcinoma
___ Adenocarcinoma
    *___ Carcinoma resembling breast carcinoma
    *___ Eccrine carcinoma
    *___ Other (specify): ____________________________
___ Paget disease
___ Other (specify): ____________________________
___ Carcinoma, type cannot be determined

Histologic Grade
___ Not applicable
___ GX: Cannot be assessed
___ G1: Well differentiated
___ G2: Moderately differentiated
___ G3: Poorly differentiated
___ G4: Undifferentiated
___ Other (specify): ____________________________

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
**Pathologic Staging (pTNM [FIGO])**

**Primary Tumor (pT)**
- ___ pTX [-]: Cannot be assessed
- ___ pT0 [-]: No evidence of primary tumor
- ___ pTis [0]: Carcinoma in situ
- ___ pT1 [I]: Tumor confined to vulva or vulva and perineum, 2 cm or less in greatest dimension
  - ___ pT1a [IA]: Tumor confined to vulva or vulva and perineum, 2 cm or less in greatest dimension, and with stromal invasion no more than 1 mm
  - ___ pT1b [IB]: Tumor confined to vulva or vulva and perineum, 2 cm or less in greatest dimension, and with stromal invasion greater than 1 mm
- ___ pT2 [II]: Tumor confined to vulva or vulva and perineum greater than 2 cm in greatest dimension
- ___ pT3 [III]: Tumor of any size with contiguous spread to the lower urethra and/or vagina or anus
- ___ pT4 [IVA]: Tumor invades any of the following: upper urethra, bladder mucosa, rectal mucosa, or is fixed to pubic bone

**Regional Lymph Nodes (pN)**
- ___ pNX: Cannot be assessed
- ___ pN0: No regional lymph node metastasis
- ___ pN1 [III]: Unilateral regional lymph node metastasis (pT1-pT3)
- ___ pN1 [IVA]: Unilateral regional lymph node metastasis (pT4)
- ___ pN1 [IVB]: Unilateral regional lymph node metastasis (pT1-pT4, pM1)
- ___ pN2 [IVA]: Bilateral regional lymph node metastasis (pT1-pT4)
- ___ pN2 [IVB]: Bilateral regional lymph node metastasis (pT1-pT4, pM1)

Specify:
- Number examined: ___
- Number involved: ___

**Distant Metastasis (pM)**
- ___ pMX: Cannot be assessed
- ___ pM1 [IVB]: Distant metastasis
  
  *Specify site(s), if known: ____________________________

**Depth of Invasion**

Specify: ___ mm
- ___ Cannot be determined (see Comment)

**Tumor Border**
- *___ Pushing
- *___ Infiltrating

---

* Data elements *with asterisks* are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
Margins (check all that apply)
___ Cannot be assessed
___ Uninvolved by invasive carcinoma
   Distance of invasive carcinoma from closest margin: ___ mm
   Specify margin, if possible: ____________________________
   ___ Carcinoma in situ absent at margin
   ___ Carcinoma in situ present at margin
___ Involved by invasive carcinoma
   Specify margin(s): ____________________________

*Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)
*___ Absent
*___ Present
*___ Indeterminate

*Additional Pathologic Findings (check all that apply)
*___ None identified
*___ Dysplasia
*___ Condyloma accuminatum
*___ Vulvar intraepithelial neoplasia 3 (VIN3: severe dysplasia/carcinoma in situ)
*___ Other (specify): ____________________________

*Comment(s)